secwatch.observer — SEC 8-K summary
======================================

Issuer:     Emergent BioSolutions Inc. (EBS)
CIK:        0001367644
Form:       8-K
Filed at:   2025-03-24T23:59:59+00:00
Accession:  0001367644-25-000083
Event type: m_and_a
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Emergent closes sale of Baltimore-Bayview facility to Syngene for ~$36.5M
-------------------------------------------------------------------------

- Sale closed on March 19, 2025; Emergent received ~$36.5M at closing, subject to post-closing adjustments.
- Syngene acquired assets and equipment of the Baltimore-Bayview drug substance manufacturing site.
- Emergent retains rights to secure manufacturing services and capacity at the facility for future growth and pandemic response.
- CEO Joe Papa says deal streamlines operations while maintaining flexibility; transaction supports multi-year turnaround.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1367644/000136764425000083/0001367644-25-000083-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1367644/000136764425000083/ebs-20250319.htm
  HTML page:      https://secwatch.observer/filing/0001367644-25-000083

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer